ORYZON announces enrollment of first patient in ESCAPE: a Phase II clinical trial with vafidemstat in severely ill COVID-19 patients

MADRID, SPAIN and CAMBRIDGE MA.

• ESCAPE study to recruit 40 patients

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in its Phase II clinical trial with vafidemstat in seriously ill COVID-19 patients.

Click here to see the full Press Release